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Published by Elsevier Inc.CORRECTIONLiu Y, Xu S. Post-Conditioning the Human Heart: Technical Concerns Beyond the Protocol Algorithm. J Am Coll
Cardiol 2013;62:1216–7.
The corresponding address for Dr. Liu was printed incorrectly; Fuwai Hospital should not have been included. The complete
correct information is below:
*Yang Liu, MD
Shaofa Xu, MD
*Department of Intensive Care Unit
Beijing Chest Hospital
Capital Medical University
No. 97 Beimachang
Tongzhou District
Beijing 101149
China
E-mail: yglv2013@126.com
We apologize for this error.
http://dx.doi.org/10.1016/j.jacc.2013.10.020
CORRECTIONWessler JD, Grip LT, Mendell J, Giugliano RP. The P-Glycoprotein Transport System and Cardiovascular Drugs.
J Am Coll Cardiol 2013;61:2495–502.
The full prescribing information for apixaban (Eliquis) on page 2499 needs to be clariﬁed: “dose reduction for apixaban
applies to coadministration of apixaban and strong dual inhibitors of both P-gp and CYP3A4.” This corrects the previous
statement that recommends dose reduction of apixaban “when administered with strong P-gp inhibitors.”
The authors apologize for this error.
http://dx.doi.org/10.1016/j.jacc.2014.04.001
